Process Validation Lifecycle
Process validation is documented evidence that a manufacturing process, operated within defined parameters, consistently produces product meeting its quality attributes. The modern view — set out in the FDA’s 2011 guidance and EU GMP Annex 15 — is a lifecycle: not a one-time three-batch event, but a continuum from process design through qualification into ongoing verification for the life of the product.
Stage 1 — Process Design
Validation begins long before the qualification batches. Stage 1 builds process understanding: identifying the critical quality attributes (CQAs) of the product and the critical process parameters (CPPs) that affect them, and establishing the design space and control strategy. This is where ICH Q8 (Pharmaceutical Development) and Quality by Design do their work — you cannot validate a process you do not understand.
A process designed on empirical "it worked last time" reasoning cannot be defended when a batch fails. A process designed on a documented understanding of what drives each CQA can be — and can be improved with confidence.
Stage 2 — Process Qualification (PPQ)
Stage 2 confirms the process design is reproducible at commercial scale. It has two elements: qualification of the facility, utilities, and equipment (the engineering foundation — see Good Engineering Practice and commissioning & qualification), and the Process Performance Qualification (PPQ) batches themselves, manufactured under the commercial control strategy and evaluated against pre-defined acceptance criteria.
The number of PPQ batches is not fixed at three. The lifecycle approach expects the number to be justified by risk and by the process understanding from Stage 1 — a well-understood, well-controlled process may justify fewer or more batches than the legacy default. EU GMP Annex 15 provides the EU expectations for qualification and validation across this stage.
Stage 3 — Continued Process Verification (CPV)
Validation is never "done". Stage 3 provides ongoing assurance that the process stays in a state of control during routine production, using statistical monitoring of parameters and attributes to detect drift and signal when action is needed. CPV turns process validation from an event into a permanent feedback loop, closely tied to the Pharmaceutical Quality System (ICH Q10).
A strong CPV programme is also a strong quality-economics story: it catches variation before it becomes a deviation, a rejected batch, or a recall — reducing the cost of poor quality while continuously improving the process.
One lifecycle, tied to the quality system
The three stages are not independent projects; they are a single lifecycle held together by the quality system. Knowledge from Stage 1 justifies Stage 2; signals from Stage 3 feed back to refine the design space and control strategy. For APIs, ICH Q7 sets the GMP baseline the whole lifecycle sits on.
Derived from the 5 standards that anchor this topic.
What are the three stages of process validation?
Stage 1 Process Design (build process understanding — CQAs, CPPs, control strategy), Stage 2 Process Qualification (confirm reproducibility at commercial scale via facility/equipment qualification and PPQ batches), and Stage 3 Continued Process Verification (ongoing statistical assurance that the process stays in control). This lifecycle model comes from the FDA’s 2011 guidance.
Do you still need three validation batches?
Not necessarily. The lifecycle approach replaced the fixed three-batch rule: the number of PPQ batches should be justified by risk and by the process understanding developed in Stage 1. A well-understood process may justify a different number, defended by data rather than convention.
How does process validation relate to Quality by Design?
Quality by Design (ICH Q8) supplies the process understanding that Stage 1 depends on — CQAs, CPPs, design space, and control strategy. Process validation then confirms and maintains that design across the product lifecycle. QbD makes validation defensible; validation makes QbD real in production.
Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.